NYSEAMERICAN:OSTX OS Therapies (OSTX) Stock Price, News & Analysis $1.88 +0.07 (+3.57%) As of 03:57 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About OS Therapies Stock (NYSEAMERICAN:OSTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OS Therapies alerts:Sign Up Key Stats Today's Range$1.84▼$1.9650-Day Range$1.44▼$2.2452-Week Range$1.15▼$2.35Volume905,206 shsAverage Volume630,622 shsMarket Capitalization$86.96 millionP/E RatioN/ADividend YieldN/APrice Target$13.33Consensus RatingModerate Buy Company Overview OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. Read More OS Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreOSTX MarketRank™: OS Therapies scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingOS Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialOS Therapies has a consensus price target of $13.33, representing about 601.8% upside from its current price of $1.90.Amount of Analyst CoverageOS Therapies has only been the subject of 1 research reports in the past 90 days.Read more about OS Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OS Therapies are expected to grow in the coming year, from ($0.77) to $0.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OS Therapies is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OS Therapies is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.19% of the float of OS Therapies has been sold short.Short Interest Ratio / Days to CoverOS Therapies has a short interest ratio ("days to cover") of 9.13.Change versus previous monthShort interest in OS Therapies has recently decreased by 6.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOS Therapies does not currently pay a dividend.Dividend GrowthOS Therapies does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for OSTX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OS Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of OS Therapies is held by insiders.Percentage Held by InstitutionsOS Therapies has minimal institutional ownership at this time.Read more about OS Therapies' insider trading history. Receive OSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSTX Stock News HeadlinesOS Therapies (NYSEAMERICAN:OSTX) Trading Down 2.5% - Time to Sell?August 25, 2026 | americanbankingnews.comOS Therapies Launches $75 Million At-The-Market OfferingAugust 21, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 4 at 1:00 AM | Stansberry Research (Ad)OS Therapies: OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in ...August 13, 2026 | finanznachrichten.deOS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully ...August 13, 2026 | finance.yahoo.comOS Therapies Announces Convertible Note Financing and WarrantsAugust 12, 2026 | tipranks.comOS Therapies Settles Leonite Debt, Issues Bridge FinancingAugust 6, 2026 | tipranks.comOS Therapies Ends At-The-Market Equity Sales ProgramJuly 29, 2026 | tipranks.comSee More Headlines OSTX Stock Analysis - Frequently Asked Questions How have OSTX shares performed this year? OS Therapies' stock was trading at $1.40 at the start of the year. Since then, OSTX stock has increased by 35.7% and is now trading at $1.90. How were OS Therapies' earnings last quarter? OS Therapies Incorporated (NYSEAMERICAN:OSTX) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. Who are OS Therapies' major shareholders? Top institutional shareholders of OS Therapies include AXQ Capital LP (0.05%). View institutional ownership trends. How do I buy shares of OS Therapies? Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today9/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 OSTX's financial health is in the Green zone, according to TradeSmith. OSTX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:OSTX Previous SymbolNYSE:OSTX CIK1795091 Webostherapies.com Phone(410) 297-7793FaxN/AEmployeesN/AYear Founded2018Price Target and Rating Average Price Target for OS Therapies$13.33 High Price Target$20.00 Low Price Target$7.00 Potential Upside/Downside+607.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.75 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-477.37% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-7.25Miscellaneous Outstanding Shares46,130,000Free Float41,698,000Market Cap$86.96 million OptionableN/A Beta-0.68 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSEAMERICAN:OSTX) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredCongress Just Opened the FloodgatesThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredFDA Momentum is Building Around NNVC!NanoViricides (NYSE: NNVC) just received regulatory approval to begin a Phase II trial of NV-387 Oral Gummies ...Smallcaps Daily | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredNear retirement? Buy this stockOn August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
